Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9166924 | 0.83 | LMNA (0.38) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL522139 | 0.82 | LMNA (0.40) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL1200922 | 0.76 | LMNA (0.44) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL522409 | 0.75 | — | — | |
| SCHEMBL14945604 | 0.75 | LMNA (0.43) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL1199895 | 0.72 | LMNA (0.48) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL8791743 | 0.71 | TSHR (0.56) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL3954839 | 0.71 | LMNA (0.39) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL14948694 | 0.71 | ALDH1A1 (0.42) | LMNAKMT2ATDP1MEN1THRB | |
| SCHEMBL27939291 | 0.70 | ALDH1A1 (0.41) | LMNAKMT2ATDP1MEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | claimed |
| US-6653468-B1 | Bicyclic heptane derivatives linked to controlled pore glass or copolymers of polystyrene; can be cleaved and used for subsequent reactions | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| EP-1181301-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000075157-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| US-20240238321-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024130217-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024130218-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240175016-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240150756-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-09 | — | — | US | disclosed |
| EP-4362933-A1 | COMPLEMENT INHIBITION | Apellis Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240132894-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-25 | — | — | US | disclosed |
| EP-4355350-A1 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4344744-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-04-03 | — | — | EP | disclosed |
| US-20240102017-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240102018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4340859-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | Biohaven Therapeutics Ltd. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | UNIVERSITAT BERN (CH) | 2024-03-05 | — | — | US | disclosed |
| WO-2024020188-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-11872239-B2 | Modified oligomeric compounds comprising tricyclo-DNA nucleosides and uses thereof | SYNTHENA AG (CH) | 2024-01-16 | — | — | US | disclosed |
| EP-4288110-A2 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230392137-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-12-07 | — | — | US | disclosed |
| WO-2023220087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | AMYLYX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| EP-4240849-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271917-A1 | AMINO ACIDS | PARABILIS MEDICINES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11739325-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-29 | — | — | US | disclosed |
| EP-4225915-A1 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | SQY Therapeutics (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| EP-4185599-A2 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4185284-A1 | AMINO ACIDS | Fog Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-11 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| WO-2023076352-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023075766-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-04 | — | — | WO | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230132377-A9 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2023-04-27 | — | — | US | disclosed |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049475-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049477-A2 | COMPOSITIONS FOR EDITING MECP2 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| EP-4153747-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153604-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| US-20230089442-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-23 | — | — | US | disclosed |
| US-11603532-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-14 | — | — | US | disclosed |
| EP-4137572-A1 | CHIRAL DESIGN | Wave Life Sciences Ltd. (SG) | 2023-02-22 | — | — | EP | disclosed |
| EP-4125893-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Biohaven Therapeutics Ltd. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2023278698-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-12-22 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022261257-A1 | STAPLED PEPTIDES AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022246086-A1 | ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-4061425-A1 | DIRECTED CONJUGATION TECHNOLOGIES | Kleo Pharmaceuticals, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-3612546-B1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2022-07-13 | — | — | EP | disclosed |
| EP-4022059-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2022-07-06 | — | — | EP | disclosed |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-23 | — | — | US | disclosed |
| US-20220186217-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-16 | — | — | US | disclosed |
| US-20220162598-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-26 | — | — | US | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| US-20220145300-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | US | disclosed |
| EP-3993818-A2 | CD38-BINDING AGENTS AND USES THEREOF | Kleo Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022073920-A1 | OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51 | SQY THERAPEUTICS (FR) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| US-20220017898-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2022-01-20 | — | — | US | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| EP-3891284-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210254062-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-08-19 | — | — | US | disclosed |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | Universität Bern (CH) | 2021-06-08 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-25 | — | — | US | disclosed |
| US-20210130821-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-06 | — | — | US | disclosed |
| US-20210115444-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-22 | — | — | US | disclosed |
| WO-2021071788-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071858-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| EP-3790968-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | Alpha Anomeric SAS (FR) | 2021-03-17 | — | — | EP | disclosed |
| US-20210032620-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-10882884-B2 | Stereoselective synthesis of phosphorothioate oligoribonucleotides | ETH ZURICH (CH) | 2021-01-05 | — | — | US | disclosed |
| US-20200390792-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200369639-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | SYNTHENA AG (CH) | 2020-11-26 | — | — | US | disclosed |
| EP-3740472-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | Synthena AG (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-20200362337-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-11-19 | — | — | US | disclosed |
| WO-2020227691-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020219981-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219983-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-10-29 | — | — | WO | disclosed |
| US-10815482-B2 | Chiral design | WAVE LIFE SCIENCES LTD. (SG) | 2020-10-27 | — | — | US | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-10724035-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-28 | — | — | US | disclosed |
| EP-3664815-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2020-06-17 | — | — | EP | disclosed |
| EP-3664816-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020118246-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-11 | — | — | WO | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| EP-3630199-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2020-04-08 | — | — | EP | disclosed |
| US-10590413-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-17 | — | — | US | disclosed |
| US-20200080083-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-12 | — | — | US | disclosed |
| EP-3612546-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | Synthena AG (CH) | 2020-02-26 | — | — | EP | disclosed |
| US-20200056173-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-02-20 | — | — | US | disclosed |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-19 | — | — | US | disclosed |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2019215333-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2019-11-14 | — | — | WO | disclosed |
| US-10450568-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-10-22 | — | — | US | disclosed |
| EP-3548502-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| EP-3523437-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2019-08-14 | — | — | EP | disclosed |
| WO-2019142135-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | SYNTHENA AG (CH) | 2019-07-25 | — | — | WO | disclosed |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-07-11 | — | — | US | disclosed |
| US-20190135849-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHOROTHIOATE OLIGORIBONUCLEOTIDES | ETH ZURICH (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-05-02 | — | — | US | disclosed |
| US-20190106696-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2019-04-11 | — | — | US | disclosed |
| EP-3463386-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2019-04-10 | — | — | EP | disclosed |
| EP-3458464-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHOROTHIOATE OLIGORIBONUCLEOTIDES | ETH Zurich (CH) | 2019-03-27 | — | — | EP | disclosed |
| EP-3452596-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019032607-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032612-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-02-14 | — | — | WO | disclosed |
| US-20190008986-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-01-10 | — | — | US | disclosed |
| US-10160969-B2 | Chiral design | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-25 | — | — | US | disclosed |
| WO-2018223056-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018193428-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | SYNTHENA AG (CH) | 2018-10-25 | — | — | WO | disclosed |
| US-20180216107-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| WO-2018099946-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2018-06-07 | — | — | WO | disclosed |
| EP-3330276-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | Universität Bern (CH) | 2018-06-06 | — | — | EP | disclosed |
| EP-3324978-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325017-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2018-05-30 | — | — | EP | disclosed |
| US-9982257-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-29 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| US-9885037-B2 | — | — | 2018-02-06 | — | — | US | disclosed |
| WO-2017198775-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHOROTHIOATE OLIGORIBONUCLEOTIDES | ETH ZURICH (CH) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
| US-20170037399-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-09 | — | — | US | disclosed |
| WO-2017015555-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015575-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-01-26 | — | — | WO | disclosed |
| EP-3094728-A2 | CHIRAL DESIGN | Wave Life Sciences Ltd. (SG) | 2016-11-23 | — | — | EP | disclosed |
| US-9303055-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| EP-2872147-A2 | CHIRAL CONTROL | Wave Life Sciences Pte. Ltd. (SG) | 2015-05-20 | — | — | EP | disclosed |
| US-8703728-B2 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1562971-B1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8461317-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8124745-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120029166-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNVERSITY OF MICHIGAN (US) | 2012-02-02 | — | — | US | disclosed |
| US-8053187-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110097762-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | THE REGENTS OF THE UNVERSITY OF MICHIGAN (US) | 2011-04-28 | — | — | US | disclosed |
| US-7807807-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | Isis Pharmaceutiacls, Inc. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20100093974-A1 | Linkers and Co-Coupling Agents for Optimization of Oligonucleotide Synthesis and Purification on Solid Supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-04-15 | — | — | US | disclosed |
| US-7696345-B2 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | AGILENT TECHNOLOGIES, INC. | 2010-02-04 | — | — | US | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7553958-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-2048149-A2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid support | The Regents of the University of Michigan (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20090075840-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | AGILENT TECHNOLOGIES, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1562971-A4 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ALLERSON CHARLES | 2008-02-14 | — | — | US | disclosed |
| EP-1373286-A4 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | UNIV MICHIGAN (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070287832-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | GAO, XIAOLIAN | 2007-12-13 | — | — | US | disclosed |
| US-7211654-B2 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-01 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| EP-1562971-A2 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | Isis Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6794502-B2 | HALF-LIFE IS DETERMINED FOR DEPROTECTION OF 5'-OH PROTECTING GROUP AT THE 5'-TERMINUS OF AN OLIGONUCLEOTIDE POST-SYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004041889-A2 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004011474-A1 | UNIVERSAL SUPPORT MEDIA FOR SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1373286-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6653468-B1 | Bicyclic heptane derivatives linked to controlled pore glass or copolymers of polystyrene; can be cleaved and used for subsequent reactions | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-0843684-B1 | UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE | BECKMAN COULTER INC (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-06-26 | — | — | US | disclosed |
| US-20020156268-A1 | Methods for removing dimethoxytrityl groups from oligonucleotides | KROTZ ACHIM H (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002072791-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6399765-B1 | DEALKYLATION USING ACID SOLUTION | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1181301-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075157-A1 | OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000055170-A1 | METHODS FOR REMOVING DIMETHOXYTRITYL GROUPS FROM OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-5869696-A | OLIGONUCLEOTIDE CLEAVING REAGENT CONSISTING OF AQUEOUS SOLUTION OF METHYLAMINE AND AQUEOUS SOLUTION OF DIMETHYLAMINE OR TRIMETHYLAMINE | BECKMAN INSTRUMENTS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0843684-A2 | UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE | BECKMAN INSTRUMENTS, INC. (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0839829-A2 | Universal solid support oligonucleotide reagents | BECKMAN INSTRUMENTS, INC. (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997040458-A2 | UNIVERSAL SOLID SUPPORTS AND METHODS FOR THEIR USE | BECKMAN INSTRUMENTS, INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | PCNA, LIG4, DCLRE1A | LMNA 1096/4885KMT2A 1385/4885TDP1 926/4885 |
| US-20200390792-A1 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | MTPN, UTRN, DCTD | LMNA 46/4885KMT2A 2603/4885TDP1 17/4885 |
| US-20040171570-A1 | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation | HNRNPC, SNRPE, IGF2BP1 | LMNA 1819/4885KMT2A 2047/4885TDP1 2307/4885 |
| US-20200369639-A1 | TRICYCLO-DNA NUCLEOSIDE PRECURSORS AND PROCESSES FOR PREPARING THE SAME | TYMP, TRDMT1, TYMS | LMNA 953/4885KMT2A 2660/4885TDP1 65/4885 |
| US-11028117-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, NUDT1, REV1 | LMNA 275/4885KMT2A 3768/4885TDP1 33/4885 |
| US-20240132894-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | LMNA 738/4885KMT2A 698/4885TDP1 253/4885 |
| US-20130261026-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | PCNA, LIG4, DCLRE1A | LMNA 1096/4885KMT2A 1385/4885TDP1 926/4885 |
| US-20240150756-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | LMNA 860/4885KMT2A 1986/4885TDP1 214/4885 |
| US-20210130821-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-20220145300-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | TARDBP, GRN, FUS | LMNA 883/4885KMT2A 2015/4885TDP1 71/4885 |
| US-20230145795-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ADAR, TRDMT1, RNMT | LMNA 381/4885KMT2A 938/4885TDP1 120/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | LMNA 4459/4885KMT2A 310/4885TDP1 1762/4885 |
| US-20190127733-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | LMNA 860/4885KMT2A 1986/4885TDP1 214/4885 |
| US-20190345188-A1 | NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM | RRM2, PRPF31, SLC29A2 | LMNA 308/4885KMT2A 3570/4885TDP1 39/4885 |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | LMNA 860/4885KMT2A 1986/4885TDP1 214/4885 |
| US-20120029166-A1 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS | PCNA, LIG4, DCLRE1A | LMNA 1096/4885KMT2A 1385/4885TDP1 926/4885 |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | LMNA 1785/4885KMT2A 2924/4885TDP1 1417/4885 |
| US-20190209604-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | LMNA 3612/4885KMT2A 1618/4885TDP1 496/4885 |
| US-20100216982-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | LMNA 1819/4885KMT2A 2047/4885TDP1 2307/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | LMNA 830/4885KMT2A 3103/4885TDP1 1738/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | LMNA 1785/4885KMT2A 2924/4885TDP1 1417/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | LMNA 1785/4885KMT2A 2924/4885TDP1 1417/4885 |
| US-11872239-B2 | Modified oligomeric compounds comprising tricyclo-DNA nucleosides and uses thereof | MTPN, UTRN, DCTD | LMNA 46/4885KMT2A 2603/4885TDP1 17/4885 |
| US-20100029513-A1 | Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules | POLM, RNGTT, POLN | LMNA 109/4885KMT2A 1878/4885TDP1 95/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | LMNA 716/4885KMT2A 742/4885TDP1 311/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | LMNA 106/4885KMT2A 4217/4885TDP1 1846/4885 |
| US-20190135849-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHOROTHIOATE OLIGORIBONUCLEOTIDES | RNGTT, TYMS, POLR2E | LMNA 4324/4885KMT2A 4304/4885TDP1 1119/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | LMNA 860/4885KMT2A 1986/4885TDP1 214/4885 |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | RNGTT, NSUN2, POLRMT | LMNA 448/4885KMT2A 918/4885TDP1 178/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | LMNA 738/4885KMT2A 698/4885TDP1 253/4885 |
| US-20230089442-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, POLM | LMNA 2460/4885KMT2A 2105/4885TDP1 307/4885 |
| US-20220401467-A1 | OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF | TLR9, RNGTT, NT5C3B | LMNA 3612/4885KMT2A 1618/4885TDP1 496/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | LMNA 1785/4885KMT2A 2924/4885TDP1 1417/4885 |
| US-11013757-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | LMNA 3612/4885KMT2A 1618/4885TDP1 496/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-20200080083-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | LMNA 448/4885KMT2A 918/4885TDP1 178/4885 |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | LMNA 141/4885KMT2A 2982/4885TDP1 103/4885 |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | LMNA 141/4885KMT2A 2982/4885TDP1 103/4885 |
| US-20080039618-A1 | POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION | HNRNPC, SNRPE, IGF2BP1 | LMNA 1819/4885KMT2A 2047/4885TDP1 2307/4885 |
| US-11603532-B2 | Oligonucleotide compositions and methods of use thereof | RNASE1, RNASEH1, RNASEL | LMNA 738/4885KMT2A 698/4885TDP1 253/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-10590413-B2 | Chiral control | RNGTT, POLI, NSUN3 | LMNA 1868/4885KMT2A 2211/4885TDP1 924/4885 |
| US-20230271917-A1 | AMINO ACIDS | NPPA, QPCTL, PTMS | LMNA 3354/4885KMT2A 1192/4885TDP1 2891/4885 |
| US-20050208588-A1 | Supports for oligomer synthesis | ILK, NOP2, PFAS | LMNA 1785/4885KMT2A 2924/4885TDP1 1417/4885 |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | LMNA 448/4885KMT2A 918/4885TDP1 178/4885 |
| US-10882884-B2 | Stereoselective synthesis of phosphorothioate oligoribonucleotides | RNGTT, TYMS, POLR2E | LMNA 4324/4885KMT2A 4304/4885TDP1 1119/4885 |
| US-20240102017-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | CAPN2, CAPN9, CAPNS1 | LMNA 252/4885KMT2A 2717/4885TDP1 182/4885 |
| US-11919922-B2 | Bicyclic nucleosides and oligomers prepared therefrom | RRM2, REV1, NUDT1 | LMNA 268/4885KMT2A 3991/4885TDP1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.